Drayton Wise

Drayton Wise is the former Chief Commercial Officer at Insmed with over 25 years of executive leadership in global biopharmaceuticals and rare disease commercialization. He is recognized for building and scaling high-performing commercial organizations, driving top-tier product launches, and delivering measurable shareholder value. At Insmed, he led the global launch of ARIKAYCE across the U.S., Europe, and Japan, establishing it as one of the top 10 non-oncology rare disease launches in the U.S. Drayton oversaw commercialization strategy, capability building, team buildout, launch strategy and readiness, along with cross-regional execution, shaping the company’s first commercial product, and strengthening global market leadership. Prior to Insmed, he held senior leadership roles at Novartis, including National Director, Cystic Fibrosis Sales & Account Management, contributing to the launch of 14 products across multiple disease areas, including the highly successful TOBI Podhaler. Drayton is known for building high performing teams, developing talent, fostering patient-focused cultures, and building trusted relationships with top medical experts, advocacy groups, and executive stakeholders.